|
Session 40-Oral Abstracts
New HIV and HCV Antiviral Agents, Prevention, and ARV Strategies
Wednesday, 10 am-12 noon; Auditorium |
| 10:00 am 146LB |
Interim Analysis of a Phase 2a Double-blind Study of TVR in Combination with pegIFN-a2a and RBV in HIV/HCV Co-infected Patients
Mark Sulkowski*1, D Dieterich2, K Sherman3, J Rockstroh4, N Adda5, L Mahnke5, V Garg5, S Gharakhanian5, S McCallister5, and V Soriano6
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Mt Sinai Sch of Med, New York, NY, US; 3Univ of Cincinnati Coll of Med, OH, US; 4Univ of Bonn, Germany; 5Vertex Pharmaceuticals Inc, Cambridge, MA, US; and 6Hosp Carlos III, Madrid, Spain |
| 10:15 am 147LB |
MMC Is Not Protective against HSV-2 Incidence but Halves the Risk of GUD Incidence: Results from the Randomized Trial of MMC to Reduce HIV in Kisumu, Kenya
Supriya Mehta*1, C Parker2, J Ndinya-Achola3, S Moses4, I Maclean4, K Agot5, and R Bailey1
1Univ of Illinois at Chicago, US; 2RTI Intl, Research Triangle Park, NC, US; 3Univ of Nairobi, Kenya; 4Univ of Manitoba, Winnipeg, Canada; and 5Impact Res and Devt Org, Kisumu, Kenya |
| 10:30 am 148LB |
A Randomized Open-label Trial of 5-Drug vs 3-Drug Standard PI-based cART Initiated during Acute and Early HIV-1 Infection: 48-Week Results
Martin Markowitz*1, T Evering1, M Caskey2, A Figueroa1, K Rodriguez1, M La Mar1, S Palmer3, V Sahi1, N Prada1, and H Mohri1
1Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 2The Rockefeller Univ, New York, NY, US; and 3Swedish Inst for Infectious Disease Control and Karolinska Inst, Solna |
| 10:45 am 149LB |
Efficacy and Safety of EFV with either Co-formulated 3TC/ZDV or FTC/TDF for Initial Treatment of HIV-1-infected Men and Women in Diverse Multinational Settings: ACTG PEARLS Study
Thomas Campbell*1, L Smeaton2, N Kumarasamy3, T Flanigan4, J Sanchez5, B Grinsztejn6, S Tripathy7, J Kumwenda8, V deGruttola2, J Hakim9, and ACTG PEARLS A5175 Study Team
1Univ of Colorado Denver Sch of Med, Aurora, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India; 4Warren Alpert Med Sch of Brown Univ, Providence, RI, US; 5Assn Civil Impacta Salud y Ed, Lima, Peru; 6Clin Res Inst Evandro Chagas, Manguinhos, Brazil; 7Natl AIDS Res Inst, Pune, India; 8Univ of Malawi Coll of Med, Blantyre; and 9Univ of Zimbabwe Coll of Hlth Sci, Harare |
| 11:00 am 150LB |
QDMRK, a Phase III Study of the Safety and Efficacy of Once Daily vs Twice Daily RAL in Combination Therapy for Treatment-naïve HIV-infected Patients
Joseph Eron*1, J Rockstroh2, J Reynes3, J Andrade-Villanueva4, J Madruga5, J Zhao6, P Sklar6, B-Y Nguyen6, and QDMRK Study Team
1Univ of North Carolina at Chapel Hill, US; 2Univ of Bonn, Germany; 3Ctr Hosp Univ Montpellier, France; 4Univ of Guadalajara, Mexico; 5Ctr de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; and 6Merck Res Labs, North Wales, PA, US |
| 11:15 am 151LB |
DTG in Subjects with HIV Exhibiting RAL Resistance: Functional Monotherapy Results of VIKING Study Cohort II
Joseph Eron*1, P Kumar2, A Lazzarin3, G Richmond4, V Soriano5, J Huang6, C Vavro7, M Ait-Khaled8, S Min7, and J Yeo8
1Univ of North Carolina at Chapel Hill Sch of Med, US; 2Georgetown Univ, Washington, DC, US; 3San Raffaele Sci Inst, Milan, Italy; 4Fort Lauderdale, FL, US; 5Inst de Salud Carlos III, Madrid, Spain; 6GlaxoSmithKline, Mississauga, Canada; 7GlaxoSmithKline, Research Triangle Park, NC, US; and 8GlaxoSmithKline, Stockley Park, Uxbridge, UK |
| 11:30 am 152LB |
GS-7340 Demonstrates Greater Declines in HIV-1 RNA than TDF during 14 Days of Monotherapy in HIV-1-infected Subjects
M Markowitz1, Andrew Zolopa*2, P Ruane3, K Squires4, L Zhong5, B Kearney5, and W Lee5
1The Rockefeller Univ, New York, NY, US; 2Stanford Univ, Palo Alto, CA, US; 3Lightsource Med, Los Angeles, CA, US; 4Thomas Jefferson Univ, Philadelphia, PA, US; and 5Gilead Sci, Foster City, CA, US |
| 11:45 am 153LB |
Immunomodulatory Effects of MVC Intensification in HIV-infected Individuals with Incomplete CD4+ T Cell Recovery during Suppressive ART
Peter Hunt*1, N Shulman2, T Hayes3, V Dahl4, N Funderburg5, O Adeyemi6, B Clagett5, B Shacklett3, M Lederman5, and S Deeks1
1Univ of California, San Francisco, US; 2Stanford Univ, Palo Alto, CA, US; 3Univ of California, Davis, US; 4Karolinska Inst, Stockholm, Sweden; 5Case Western Reserve Univ, Cleveland, OH, US; and 6Rush Univ, Chicago, IL, US |
|
